176 related articles for article (PubMed ID: 22080802)
1. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F
J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802
[TBL] [Abstract][Full Text] [Related]
2. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
[TBL] [Abstract][Full Text] [Related]
3. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Kralj E; Trontelj J; Pajič T; Kristl A
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
7. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
8. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Kantarjian H; Cortes J
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
[TBL] [Abstract][Full Text] [Related]
11. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Birch M; Morgan PE; Handley S; Ho A; Ireland R; Flanagan RJ
Biomed Chromatogr; 2013 Mar; 27(3):335-42. PubMed ID: 22886846
[TBL] [Abstract][Full Text] [Related]
12. [TKI therapy for CML].
Ohnishi K
Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
14. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
16. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
17. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
19. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
